Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A for treatment-resistant migraine and tension headache
IRCT20250308064974N1Phase 3Completed
- Sponsor
- Qom University of Medical Sciences
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of botulinum toxin type A in migraine and tension-type headache (TTH) (2 arms), sponsored by Qom University of Medical Sciences. Primary endpoints: Change in headache frequency, Change in headache severity and 2 more. Started Oct 2025; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
migrainetension-type headache (TTH)
Beyond the preview
Go deeper on IRCT20250308064974N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250308064974N1.